If Novo Nordisk A/S’s wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen Inc.’s Chief Executive Officer Chris Viehbacher doesn’t see it as a roadblock for his company’s medication. Rather, he sees it as an opportunity to potentially combine drugs and create a more potent therapy.\n\n“As we look out over the next five years, we’re probably going to see a treatment much like any other complex disease,” he said in an interview with Bloomberg News, meaning there will be “different mechanisms of action that you need.”\n\nIt’s not uncommon for drugmakers to study combinations of treatments when two seem to work for the same condition, in hope of boosting the benefit. Viehbacher said if Novo’s study works, Biogen “might” do trials looking at the two drugs in combination but cautioned the timeline might not make sense given Alzheimer’s studies take years to complete.\n\nBiogen’s looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple sclerosis franchise, which is facing competition from cheaper generic drugs. Biogen’s new Alzheimer’s drug is already facing competition from Eli Lilly & Co.’s Alzheimer’s drug, which was approved in the US last year and has since captured around 30 percent of the market, according to analysts.\n\nOther companies are also circling. Novo is carrying out clinical trials to assess whether the main ingredient in diabetes drug Ozempic and weight-loss shot Wegovy might help people with early Alzheimer’s disease. Research suggests that the weight-loss drug could slow Alzheimer’s progression by impacting inflammation and vascular health. Results of Novo’s late-stage trial are expected later this year.\n\nViehbacher noted that being overweight is a risk factor for Alzheimer’s. He cautioned the Novo study “is a fairly risky proposition,” adding that “most of the experts we’re talking to are not convinced that it will work.”\n\n“It’s logical if you have a weight-loss drug that you can see some benefit, but it’s actually pretty hard to move the needle on the cognitive side,” Viehbacher added. Alzheimer’s drug development has been riddled with failures, even when drugs looked promising in early studies.\n\nLeqembi is a partnership between Cambridge, Massachusetts-based Biogen and Japanese drugmaker Eisai Co.\n\nBiogen makes the active ingredient for Leqembi in Switzerland. The company then ships it to North Carolina, where it gets made into a product. President Donald Trump recently put a 39 percent tariff on imports from Switzerland. It’s unclear whether this would impact Biogen’s drug.\n\nStill, Viehbacher said the company has the ability to start producing the substance used to make Leqembi in North Carolina for the US market, while continuing to make it in Switzerland for outside the US. He said the company always intended to use its North Carolina facilities to make Leqembi and the potential move was not a direct response to Trump’s tariff threats.\n\nLast month, Biogen announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park.

Biogen sees potential in combining Alzheimer's and obesity drugs

Biogen Inc. CEO Chris Viehbacher views Novo Nordisk's potential success in using its weight-loss drug for Alzheimer's disease as an opportunity rather than a roadblock. He suggests combining Alzheimer's and obesity drugs could lead to more effective therapies, though timelines remain uncertain due to the lengthy nature of Alzheimer's drug development. Biogen is leveraging its Alzheimer's drug Leqembi to offset declining sales in its multiple sclerosis franchise, which faces competition from cheaper generics. Leqembi is a joint venture between Biogen and Eisai Co. Biogen produces the active ingredient in Switzerland and manufactures the final product in North Carolina. The company plans to invest an additional $2 billion in its North Carolina manufacturing facilities in Research Triangle Park, a move not directly tied to recent U.S. tariffs on Swiss imports. Novo Nordisk is conducting clinical trials on its diabetes and weight-loss drugs Ozempic and Wegovy for early Alzheimer's, with results expected later this year. Experts remain skeptical about the drug's effectiveness in improving cognitive outcomes.